Mevalonate Pathway – Function, Steps and Significance

What Is the Mevalonate Pathway?

The mevalonate pathway (also known as the mevalonic acid pathway or HMG-CoA reductase pathway) is a fundamental biochemical pathway present in virtually all animal cells, fungi, and many bacteria. It is responsible for the biosynthesis of isoprenoid compounds, including cholesterol, steroid hormones, bile acids, fat-soluble vitamins (such as vitamin K and vitamin D), coenzyme Q10 (ubiquinone), and dolichols. The pathway takes its name from mevalonic acid (mevalonate), a key intermediate produced during the reaction sequence.

Steps of the Mevalonate Pathway

The mevalonate pathway consists of a series of enzymatic reactions proceeding in several stages:

• Step 1 – Acetyl-CoA condensation: Two molecules of acetyl-CoA are condensed by the enzyme thiolase to form acetoacetyl-CoA.
• Step 2 – HMG-CoA formation: Acetoacetyl-CoA reacts with another acetyl-CoA molecule via HMG-CoA synthase to yield 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA).
• Step 3 – Mevalonate synthesis (rate-limiting step): HMG-CoA is reduced to mevalonic acid (mevalonate) by the enzyme HMG-CoA reductase, consuming two molecules of NADPH. This is the most tightly regulated and rate-limiting step of the entire pathway, and the primary target of statin drugs.
• Step 4 – Phosphorylation of mevalonate: Mevalonate is successively phosphorylated by specific kinases, first to mevalonate-5-phosphate and then to mevalonate-5-pyrophosphate.
• Step 5 – Formation of isopentenyl pyrophosphate (IPP): Decarboxylation of mevalonate-5-pyrophosphate produces isopentenyl pyrophosphate (IPP), the universal five-carbon (C5) isoprenoid building block.
• Step 6 – Condensation to farnesyl pyrophosphate: IPP and its isomer dimethylallyl pyrophosphate (DMAPP) are sequentially condensed to form geranyl pyrophosphate (GPP, C10) and then farnesyl pyrophosphate (FPP, C15).
• Step 7 – Divergence to squalene and cholesterol: Two molecules of FPP are joined to form squalene (C30), which is subsequently converted to cholesterol and other sterols. FPP also serves as a precursor for coenzyme Q10, dolichols, and protein prenylation reactions.

Biological Significance and Products

The mevalonate pathway generates a wide range of biologically indispensable compounds:

• Cholesterol: An essential structural component of cell membranes and the precursor molecule for steroid hormones (e.g., cortisol, aldosterone, sex hormones), bile acids, and vitamin D.
• Coenzyme Q10 (ubiquinone): A critical electron carrier in the mitochondrial respiratory chain and an important antioxidant.
• Dolichols: Involved in the N-glycosylation of proteins in the endoplasmic reticulum.
• Isopentenyl adenosine: A modified base found in certain transfer RNA molecules.
• Protein prenylation: Farnesyl pyrophosphate and geranylgeranyl pyrophosphate serve as prenyl anchors for the post-translational modification of signaling proteins (e.g., Ras proteins), regulating their membrane association and biological activity.

Regulation of the Mevalonate Pathway

The mevalonate pathway is subject to tight cellular regulation to prevent both overproduction and deficiency of cholesterol and other isoprenoids:

• Transcriptional regulation via SREBPs: When intracellular cholesterol levels fall, sterol regulatory element-binding proteins (SREBPs) are activated and upregulate the expression of HMG-CoA reductase and other pathway enzymes.
• Feedback inhibition: Elevated cholesterol concentrations directly inhibit HMG-CoA reductase and promote its accelerated degradation.
• Hormonal influences: Insulin stimulates the pathway, while glucagon and glucocorticoids inhibit it.

Pharmacological Relevance: Statins and the Mevalonate Pathway

The mevalonate pathway is the primary pharmacological target of statins (e.g., simvastatin, atorvastatin, rosuvastatin). Statins competitively inhibit HMG-CoA reductase, thereby reducing hepatic cholesterol biosynthesis. This leads to increased expression of LDL receptors on the surface of liver cells, enhancing the uptake of LDL-cholesterol from the bloodstream and lowering total cholesterol levels. Statins are widely used for the treatment and prevention of cardiovascular diseases such as atherosclerosis, myocardial infarction, and stroke.

A well-recognized side effect of statins is the secondary inhibition of coenzyme Q10 synthesis, since coenzyme Q10 is also a downstream product of the mevalonate pathway. In some cases, this may contribute to statin-associated myopathy, characterized by muscle weakness and muscle pain.

Mevalonate Pathway and Disease

Disruptions in the mevalonate pathway can lead to various clinical conditions:

• Mevalonate kinase deficiency (MKD): A rare autosomal recessive defect in the enzyme mevalonate kinase leads to accumulation of mevalonic acid, resulting in periodic fever syndromes and developmental abnormalities (mevalonic aciduria).
• Hyperlipoproteinemias: Dysregulation of the mevalonate pathway contributes to elevated blood lipid levels and cardiovascular risk.
• Cancer research: Overactivation of the mevalonate pathway has been associated with the proliferation of certain tumors, as cancer cells have an increased demand for isoprenoids to support cell growth and membrane biosynthesis.

References

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-430. doi:10.1038/343425a0
2. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160-1164. doi:10.1126/science.1059344
3. Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics. 1993;91(5):915-921.